Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
08/2003
08/07/2003WO2003064606A2 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003WO2003064471A2 Gene for peripheral arterial occlusive disease
08/07/2003WO2003064467A1 A complex of a human foxc2 protein and a foxc2-interacting protein
08/07/2003WO2003064463A2 Pluripotency determining factors and uses thereof
08/07/2003WO2003064457A1 A method for inhibiting 'melanoma inhibitory activity' mia
08/07/2003WO2003064456A1 Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
08/07/2003WO2003064455A2 Macrocyclic peptides active against the hepatitis c virus
08/07/2003WO2003064451A2 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
08/07/2003WO2003064449A2 Bioactive keratin peptides
08/07/2003WO2003064448A2 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli
08/07/2003WO2003064440A1 Compounds that inhibit factor xa activity
08/07/2003WO2003064429A1 Thienopyrimidines, process for preparing the same and use thereof
08/07/2003WO2003064426A1 N, n'-dimethylated n-confused porphyrins
08/07/2003WO2003064425A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003WO2003064423A1 Aza-arylpiperazines
08/07/2003WO2003064419A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
08/07/2003WO2003064417A1 Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
08/07/2003WO2003064411A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
08/07/2003WO2003064410A1 Novel 1,2,4-triazole compound
08/07/2003WO2003064409A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003WO2003064404A1 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
08/07/2003WO2003064402A1 Treatment of male sexual dysfunction
08/07/2003WO2003064397A1 Indazole compounds useful as protein kinase inhibitors
08/07/2003WO2003064395A1 Preventive or therapeutic agents for neurodegenerative diseases
08/07/2003WO2003064392A1 Process for the manufacture of hmg-coa reductase inhibitors
08/07/2003WO2003064391A1 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
08/07/2003WO2003064388A2 Process for the preparation of high purity perindopril and intermediates useful in the synthesis
08/07/2003WO2003064387A2 Substituted indoles as alpha-1 agonists
08/07/2003WO2003064378A2 Novel compounds that inhibit factor xa activity
08/07/2003WO2003064376A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)
08/07/2003WO2003064375A1 New opioid derivative
08/07/2003WO2003064369A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003WO2003063906A1 Drugs for treating inflammatory diseases
08/07/2003WO2003063905A1 Preventives or remedies for immunological diseases
08/07/2003WO2003063900A1 Process for the preparation of a nutrient formulation
08/07/2003WO2003063894A1 Insulin resistance improving agents
08/07/2003WO2003063893A2 Fgfr agonists
08/07/2003WO2003063892A1 Use of apelin
08/07/2003WO2003063891A1 Compositions and methods for modulating connexin hemichannels
08/07/2003WO2003063880A1 Disruption of islet amyloid by polycyclic compounds
08/07/2003WO2003063878A1 Use of polyunsaturated ketones for the treatment of psoriasis
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063874A1 Condensed heterocyclic compounds
08/07/2003WO2003063871A1 Phenylpyrimidine amines as ige inhibitors
08/07/2003WO2003063869A1 Anti-viral compounds
08/07/2003WO2003063868A1 Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
08/07/2003WO2003063864A2 Heterocyclic compounds which are active as inhibitors of beta lactamases
08/07/2003WO2003063861A1 Fibrosis inhibitor
08/07/2003WO2003063850A1 Medicinal compositions containing vitamin k’s as nerve growth factor potentiator and utilization thereof
08/07/2003WO2003063840A2 Transmucosal delivery of proton pump inhibitors
08/07/2003WO2003063837A1 Increased-dosage nelfinavir tablet and method of making same
08/07/2003WO2003063834A1 Multi-stage oral drug controlled-release system
08/07/2003WO2003063832A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003WO2003063831A2 Immediate release dosage forms containing solid drug dispersions
08/07/2003WO2003063828A1 Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
08/07/2003WO2003063822A2 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
08/07/2003WO2003063821A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003WO2003063800A2 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/07/2003WO2003063796A2 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003WO2003063794A2 2,4-pyrimidinediamine compounds and their uses
08/07/2003WO2003063792A2 Compositions and methods related to tim-3, a th1-specific cell surface molecule
08/07/2003WO2003063782A2 Kappa-pviia-related conotoxins as organ protectants
08/07/2003WO2003063771A2 N4-acylcytosine nucleosides for treatment of viral iinfections
08/07/2003WO2003063758A2 Bicyclic cb2 cannabinoid receptor ligands
08/07/2003WO2003063576A2 Arylsulfonamidobenzylic compounds
08/07/2003WO2003063573A2 Method for treating diseases with omega interferon
08/07/2003WO2003052091A8 Growth factor modified protein matrices for tissue engineering
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2003018788B1 Improved nitroreductase enzymes
08/07/2003WO2003009835A3 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
08/07/2003WO2003004034B1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
08/07/2003WO2002092825B1 Retroviral vectors for gene therapy
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002033119A3 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
08/07/2003WO2002018608A9 Methods for enhancing the efficacy of cancer therapy
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149294 Process for the preparation of latanoprost
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149266 Administering to a patient (a warm blooded animal, such as man) an effective amount of a pyrimidine derivative for treating cancer, cell proliferation, and inhibition of focal adhesion kinase effect
08/07/2003US20030149249 Process for isolation of osteopontin from milk
08/07/2003US20030149246 Macromolecular conjugates and processes for preparing the same
08/07/2003US20030149244 Adjusting affinity of Fab 27/26 fragments/polypeptides generating improved ragweed-induced histamine release inhibition; bronchodilator agents
08/07/2003US20030149236 Nucleotide sequences coding interleukin (IL)-11 receptor for development of agonists, antagonists, therapeutic and diagnostic reagents; antiproliferative/inflammatory agents
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149110 For use as as neuro-protective agents for therapy of conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine
08/07/2003US20030149101 Administering combination of a cholesterol lowering drug and an angiotensin converting enzyme inhibitor for therapy of atherosclerosis
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149093 For therapy of dyspepsia, early satiety, bloating and anorexia
08/07/2003US20030149090 Topically delivering an effective dose of a reactvie oxygen metabolites (ROM) production and release inhibitory compound in carrier to a subject suffering from ROM-mediated oxidative damage
08/07/2003US20030149086 EP4 receptor selective agonists in the treatment of osteoporosis
08/07/2003US20030149085 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
08/07/2003US20030149083 For therapy of inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic erythematodes, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis
08/07/2003US20030149075 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals
08/07/2003US20030149065 Arylkylamine spirofuropyridines useful in therapy
08/07/2003US20030149064 Pyrimidine compounds
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149057 Anti-cancer compounds
1 ... 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 ... 1564